Adial Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Adial Pharmaceuticals, Inc (ADIL)
US:NASDAQ Investor Relations:
adialpharma.com
Company Research
Source: GlobeNewswire
GLEN ALLEN, Va., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the third quarter of 2024. Cary Claiborne, President and Chief Executive Officer of Adial, stated, “We reached an important milestone this quarter with the successful database lock of the pharmacokinetics study for AD04, our lead investigational, genetically targeted therapeutic for the treatment of Alcohol Use Disorder (AUD). The pharmacokinetics study is essential for validating AD04’s dosing and safety profile, and we expect to report topline results soon. This accomplishment would position us to begin regulatory preparations, reinforcing our mission to bring a safe, effective AUD treatment to market.” “Building on our commitment to personalized
Show less
Read more
Impact Snapshot
Event Time:
ADIL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADIL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADIL alerts
High impacting Adial Pharmaceuticals, Inc news events
Weekly update
A roundup of the hottest topics
ADIL
News
- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) was upgraded by analysts at RODMAN&RENSHAW to a "strong-buy" rating.MarketBeat
- Adial Pharmaceuticals Announces Positive Topline Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder [Yahoo! Finance]Yahoo! Finance
- Adial Pharmaceuticals Announces Positive Topline Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use DisorderGlobeNewswire
- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $8.00 price target on the stock.MarketBeat
- Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial OfficerGlobeNewswire
ADIL
Sec Filings
- 11/18/24 - Form 8-K
- 11/18/24 - Form 4
- 11/18/24 - Form 3
- ADIL's page on the SEC website